This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
« Back
Page 1 of 22

MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter

By Adam Feuerstein

Afrezza is "modestly effective" at reducing blood glucose and its long-term safety is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.

08:15AM 03/02/15

Ampio Too Busy to Tell Investors Results of Eye Drug Study

By Adam Feuerstein

Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.

07:55AM 02/25/15

Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus

By Adam Feuerstein

The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.

03:47PM 02/20/15

Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price

By Adam Feuerstein

Achillion Pharmaceuticals announced a 10 million-share stock offering Tuesday night.

09:04AM 02/11/15

Well-Fed Analysts Stay Mum on Keryx Biopharma's Slow Drug Launch

By Adam Feuerstein

Keryx Biopharmaceuticals gave all 12 of the investment banks with research coverage of the company a slice of its $110 million stock offering.

08:36AM 02/09/15

Isis Pharma Time Shifts Diabetes Drug Trial to Embellish Results

By Adam Feuerstein

An experimental diabetes drug from Isis looks good when the effect is measured at 36 weeks, but the study was designed to measure the end point at 27 weeks.

07:59AM 02/03/15

Gilead: Hepatitis C Sales Guidance for 2015 Focus of Tuesday's Earnings Report

By Adam Feuerstein

Gilead Sciences reports fourth-quarter and 2014 earnings on Tuesday after the market close.

12:22PM 02/02/15

Dendreon's Asset Rummage Sale Completes the Circle of Life

By Adam Feuerstein

Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.

06:01AM 01/30/15

The Absurdity of Flex Pharma IPO: 2 Spices and a Veg Net $86M

By Adam Feuerstein

If the biotech bull market hasn't reached 11 on the absurdity meter quite yet, the Flex Pharma FLKS IPO gets us close.

07:44AM 01/29/15

Aegerion Target of SEC Probe Related to Drug Sales Practices

By Adam Feuerstein

Aegerion slipped disclosure of the SEC probe into an regulatory filing last night.

09:12AM 01/13/15

« Back
Page 1 of 22

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs